Neuromuscular Disorders Market Report 2026

The neuromuscular disorders market size has grown strongly in recent years. It will grow from $8.31 billion in 2025 to $8.98 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing prevalence of genetic neuromuscular conditions, rising awareness about early diagnosis and treatment options, growing demand for effective therapies for rare disorders, increasing research initiatives in muscular dystrophy and ALS, and rising adoption of advanced diagnostic technologies.

The neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $12.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising patient advocacy and support group activities, growing demand for biologics and gene therapies, increasing recognition of neuromuscular disorders in pediatrics, rising government initiatives for rare disease management, and growing emphasis on home-based care and rehabilitation services. Major trends in the forecast period include advancement in gene-editing technologies for targeted therapies, innovation in RNA-based treatment platforms, integration of AI for faster neuromuscular diagnosis, advancement in stem-cell-based regenerative treatments, and innovation in wearable devices for continuous patient monitoring.

The growing demand for personalized medicine is expected to drive the growth of the neuromuscular disorders market in the coming years. Personalized medicine is an approach that tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. This demand is rising due to advancements in genomic technologies, which enable precise identification of genetic variations and the development of targeted therapies. Personalized medicine enhances the management of neuromuscular disorders by customizing treatments according to individual genetic, molecular, and physiological profiles, improving patient outcomes through targeted therapies, optimized efficacy, and reduced adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from 12 approvals in 2022. Consequently, the rising demand for personalized medicine is fueling the growth of the neuromuscular disorders market.

Leading companies in the neuromuscular disorders market are focusing on developing advanced therapies, such as gene replacement treatments, to target the underlying genetic causes of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy involves engineered biological products that deliver functional copies of defective genes to restore or improve muscle function in patients with inherited neuromuscular disorders, offering a potential one-time treatment that reduces the need for long-term chronic therapy. For example, in November 2025, Novartis, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve), the first and only gene replacement therapy for children aged two years and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in the survival motor neuron 1 (SMN1) gene. The therapy is designed to address the genetic cause of SMA with a single, fixed dose that does not require adjustments for body weight or age. Itvisma can improve motor function by replacing the SMN1 gene, potentially reducing the need for long-term medications used alongside existing treatments for this patient population.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed sum. This acquisition strengthened Novartis’s RNA-based therapeutic capabilities by incorporating DTx’s proprietary FALCON siRNA platform and advancing early-stage programs targeting neuromuscular disorders, including Charcot‑Marie‑Tooth disease type 1A. DTx Pharma Inc. is a US-based biotechnology company focused on developing siRNA therapies for neurological and neuromuscular conditions.

Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.

North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuromuscular disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the neuromuscular disorders market by increasing costs of imported biologics, gene therapy components, diagnostic instruments, and assistive medical devices. north america and europe are significantly affected due to reliance on specialized pharmaceutical imports, while asia-pacific faces pricing pressure on advanced treatment solutions. these tariffs are increasing therapy costs and impacting patient access. however, they are also supporting domestic biopharmaceutical manufacturing, local diagnostic development, and regional innovation in rare disease treatments.

Neuromuscular disorders are a group of medical conditions that impact the nerves and muscles, causing weakness, loss of movement, or impaired function. They arise when communication between the nervous system and muscles is disrupted due to genetic, autoimmune, or degenerative factors. These disorders often worsen over time and require continuous medical management, therapy, and supportive care.

The key disease categories of neuromuscular disorders include SMA, ALS, DMD, myasthenia gravis, and others. SMA is a genetic disease causing progressive motor neuron loss and muscle weakness. Product types include drugs, biologics, diagnostics, and assistive devices. Routes include oral, injectable, and others. Treatments include gene therapy, drug therapy, RNA-based therapy, enzyme replacement, rehabilitation, and respiratory care.

The neuromuscular disorders market consists of revenues earned by entities through diagnostic testing, therapeutic interventions, genetic counseling, rehabilitation therapy, and long-term patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.